Raymond James & Associates Cytosorbents Corp Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Cytosorbents Corp stock. As of the latest transaction made, Raymond James & Associates holds 50,000 shares of CTSO stock, worth $45,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$45,000
Previous $35,000
114.29%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CTSO
# of Institutions
57Shares Held
16.7MCall Options Held
15.4KPut Options Held
0-
Avenir Corp Washington, DC2.98MShares$2.68 Million0.45% of portfolio
-
Skylands Capital, LLC2.76MShares$2.48 Million0.6% of portfolio
-
Granahan Investment Management, LLC Waltham, MA2.09MShares$1.89 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.75 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.78MShares$1.6 Million0.0% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $39.2M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...